Mithra Pharmaceuticals SA
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mithra Pharmaceuticals SA
Following a trio of complete response letters received since late 2018, Mayne Pharma and partner Mithra Pharmaceuticals have finally obtained US FDA approval for a generic version of Organon’s NuvaRing vaginal hormonal contraceptive ring.
Close to 90% of the FDA’s 2021 first half novel approvals were cleared in the US before Europe, while the EU’s EMA acted first on only 15% of its first half marketing authorizations for new active substances. Exclusive Pink Sheet analysis explores use of expedited review schemes, special pathways and other comparative trends.
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include five new products, including Roche’s Enspryng for neuromyelitis optica spectrum disorder.
Private Company Edition: venBio’s new fund plus Ysios Capital’s recent €216m ($260m) fund adds up to $810m in fresh venture capital for life science companies. Also, Nikang and Esco attracted $200m each in VC investment, Pulmocide closed a $92m series C round and Stablix launched with $63m.
- Other Names / Subsidiaries
- Estetra SA
- Estetra SPRL
- Mithra IBD SA
- Mithra RDP SA
- Mithra Pharmaceuticals CDMO